Yasuhiro Shiba

Title: Yasuhiro Shiba: Innovator in Cancer Therapy

Introduction

Yasuhiro Shiba is a prominent inventor based in Kanagawa, Japan. He has made significant contributions to the field of cancer therapy through his innovative research and development of anti-CDH3 antibodies. With a total of 2 patents, his work is paving the way for advancements in targeted cancer treatments.

Latest Patents

Yasuhiro Shiba's latest patents focus on anti-CDH3 antibodies and their applications in cancer therapy. The first patent, titled "Anti-CDH3 antibodies and uses thereof," describes antibodies that can be labeled with a radioisotope. This invention provides methods and pharmaceutical compositions that utilize anti-CDH3 antibodies as active ingredients. Given that CDH3 is strongly expressed in various cancer cells, including pancreatic, lung, colon, prostate, breast, gastric, and liver cancers, this invention holds promise for effective therapies in these areas. The second patent, "Anti-CDH3 antibodies labeled with radioisotope label and uses thereof," reiterates the same innovative concepts, emphasizing the potential of these antibodies in cancer treatment.

Career Highlights

Yasuhiro Shiba is currently associated with Oncotherapy Science, Incorporated, where he continues to advance his research in oncology. His work is instrumental in developing targeted therapies that can improve patient outcomes in cancer treatment.

Collaborations

Yasuhiro collaborates with notable colleagues, including Hiroki Yoshioka and Pohsing Ng, who contribute to his research efforts and innovations in the field.

Conclusion

Yasuhiro Shiba's contributions to cancer therapy through his patents on anti-CDH3 antibodies highlight his role as an innovator in the medical field. His work is expected to have a lasting impact on cancer treatment methodologies.